| Schedule of Intangible Assets |
Intangible assets were as follows as of November 30, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
|
|
Useful lives |
|
November 30, 2023 |
|
|
November 30, 2022 |
|
Patents |
|
10-20 years |
|
$ |
697,744 |
|
|
$ |
697,744 |
|
Less: Intangible asset impairment |
|
|
|
|
(377,810 |
) |
|
|
— |
|
Less: Accumulated amortization |
|
|
|
|
(160,434 |
) |
|
|
(120,297 |
) |
License agreement |
|
10 years |
|
|
474,000 |
|
|
|
474,000 |
|
Less: Intangible asset impairment |
|
|
|
|
(185,000 |
) |
|
|
(185,000 |
) |
Less: Accumulated amortization |
|
|
|
|
(248,607 |
) |
|
|
(225,157 |
) |
Customer relationships – PrepaCyte®CB |
|
15 years |
|
|
41,000 |
|
|
|
41,000 |
|
Less: Intangible asset impairment |
|
|
|
|
(26,267 |
) |
|
|
(26,267 |
) |
Less: Accumulated amortization |
|
|
|
|
(9,505 |
) |
|
|
(8,711 |
) |
Brand |
|
1 year |
|
|
31,000 |
|
|
|
31,000 |
|
Less: Accumulated amortization |
|
|
|
|
(31,000 |
) |
|
|
(31,000 |
) |
Customer relationships – Cord:Use |
|
30 years |
|
|
960,000 |
|
|
|
960,000 |
|
Less: Accumulated amortization |
|
|
|
|
(176,000 |
) |
|
|
(144,000 |
) |
Net Intangible Assets |
|
|
|
$ |
989,121 |
|
|
$ |
1,463,312 |
|
|
| Schedule of Expected Amortization Expenses |
Expected amortization related to these intangible assets for each of the next five fiscal years and for periods thereafter is as follows:
|
|
|
|
|
Fiscal years ending November 30: |
|
|
|
2024 |
|
$ |
67,867 |
|
2025 |
|
$ |
58,180 |
|
2026 |
|
$ |
44,618 |
|
2027 |
|
$ |
44,618 |
|
2028 |
|
$ |
44,618 |
|
Thereafter |
|
$ |
729,220 |
|
Total |
|
$ |
989,121 |
|
|